JP2007503812A - 空間構造によるタンパク質の機能の調節 - Google Patents
空間構造によるタンパク質の機能の調節 Download PDFInfo
- Publication number
- JP2007503812A JP2007503812A JP2006524917A JP2006524917A JP2007503812A JP 2007503812 A JP2007503812 A JP 2007503812A JP 2006524917 A JP2006524917 A JP 2006524917A JP 2006524917 A JP2006524917 A JP 2006524917A JP 2007503812 A JP2007503812 A JP 2007503812A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- codon
- function
- gene
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000033228 biological regulation Effects 0.000 title description 2
- 230000004853 protein function Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 80
- 108020004705 Codon Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 29
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 108700010070 Codon Usage Proteins 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 description 21
- 102000014150 Interferons Human genes 0.000 description 21
- 101710142246 External core antigen Proteins 0.000 description 14
- 239000013078 crystal Substances 0.000 description 14
- 229940079322 interferon Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 241000700721 Hepatitis B virus Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940090438 infergen Drugs 0.000 description 8
- 108010010648 interferon alfacon-1 Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000031636 Body Temperature Changes Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49878503P | 2003-08-28 | 2003-08-28 | |
| US49844903P | 2003-08-28 | 2003-08-28 | |
| US49892303P | 2003-08-28 | 2003-08-28 | |
| IN279MU2004 | 2004-03-05 | ||
| IN280MU2004 | 2004-03-05 | ||
| PCT/US2004/028068 WO2005021777A2 (en) | 2003-08-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011011325A Division JP2011083292A (ja) | 2003-08-28 | 2011-01-21 | 空間構造によるタンパク質の機能の調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503812A true JP2007503812A (ja) | 2007-03-01 |
| JP2007503812A5 JP2007503812A5 (OSRAM) | 2007-12-06 |
Family
ID=34280101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524917A Pending JP2007503812A (ja) | 2003-08-28 | 2004-08-26 | 空間構造によるタンパク質の機能の調節 |
| JP2006524916A Expired - Fee Related JP5663768B2 (ja) | 2003-08-28 | 2004-08-26 | 空間構造が変えられるインターフェロン及びその応用 |
| JP2011011325A Pending JP2011083292A (ja) | 2003-08-28 | 2011-01-21 | 空間構造によるタンパク質の機能の調節 |
| JP2012121307A Expired - Fee Related JP5709800B2 (ja) | 2003-08-28 | 2012-05-28 | 変えられた空間構造を備えるインターフェロン及びその応用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524916A Expired - Fee Related JP5663768B2 (ja) | 2003-08-28 | 2004-08-26 | 空間構造が変えられるインターフェロン及びその応用 |
| JP2011011325A Pending JP2011083292A (ja) | 2003-08-28 | 2011-01-21 | 空間構造によるタンパク質の機能の調節 |
| JP2012121307A Expired - Fee Related JP5709800B2 (ja) | 2003-08-28 | 2012-05-28 | 変えられた空間構造を備えるインターフェロン及びその応用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (3) | EP2325202B1 (OSRAM) |
| JP (4) | JP2007503812A (OSRAM) |
| KR (2) | KR20060133949A (OSRAM) |
| AU (2) | AU2004269390A1 (OSRAM) |
| CA (2) | CA2535902A1 (OSRAM) |
| PL (2) | PL2325202T3 (OSRAM) |
| WO (2) | WO2005021777A2 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013514279A (ja) * | 2009-12-18 | 2013-04-25 | 四川▲輝▼▲陽▼生命工程股▲分▼有限公司 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
| JP2016506413A (ja) * | 2013-01-07 | 2016-03-03 | スーパーラブ ファー イースト リミテッド | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2022516129A (ja) * | 2018-12-26 | 2022-02-24 | 上海元宋生物技術有限公司 | インターフェロンを発現する腫瘍溶解性ウイルス及びその応用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| WO2005021777A2 (en) * | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
| US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| WO2006076014A2 (en) * | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| EP1868636A4 (en) * | 2005-03-09 | 2012-03-28 | Guangwen Wei | USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514868A (ja) * | 1995-10-13 | 1999-12-21 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ホスホパンテテイニルトランスフェラーゼおよびその使用 |
| JP2000503536A (ja) * | 1996-01-18 | 2000-03-28 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド | ヒト化グリーン蛍光タンパク質遺伝子および方法 |
| WO2002080958A1 (fr) * | 2001-02-28 | 2002-10-17 | Sichuan Biotechnology Research Center | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
| IL155741A0 (en) * | 2000-11-03 | 2003-12-23 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| WO2005021777A2 (en) * | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
-
2004
- 2004-08-26 WO PCT/US2004/028068 patent/WO2005021777A2/en not_active Ceased
- 2004-08-26 JP JP2006524917A patent/JP2007503812A/ja active Pending
- 2004-08-26 WO PCT/US2004/028067 patent/WO2005034853A2/en not_active Ceased
- 2004-08-26 EP EP10193126.9A patent/EP2325202B1/en not_active Expired - Lifetime
- 2004-08-26 CA CA002535902A patent/CA2535902A1/en not_active Abandoned
- 2004-08-26 AU AU2004269390A patent/AU2004269390A1/en not_active Abandoned
- 2004-08-26 EP EP04782529A patent/EP1670817A4/en not_active Ceased
- 2004-08-26 AU AU2004279350A patent/AU2004279350B2/en not_active Expired
- 2004-08-26 KR KR1020067003700A patent/KR20060133949A/ko not_active Ceased
- 2004-08-26 EP EP04809634.1A patent/EP1663110B1/en not_active Expired - Lifetime
- 2004-08-26 PL PL10193126T patent/PL2325202T3/pl unknown
- 2004-08-26 PL PL04809634T patent/PL1663110T3/pl unknown
- 2004-08-26 CA CA2535982A patent/CA2535982C/en not_active Expired - Lifetime
- 2004-08-26 JP JP2006524916A patent/JP5663768B2/ja not_active Expired - Fee Related
- 2004-08-26 KR KR1020067003699A patent/KR20060130009A/ko not_active Ceased
-
2011
- 2011-01-21 JP JP2011011325A patent/JP2011083292A/ja active Pending
-
2012
- 2012-05-28 JP JP2012121307A patent/JP5709800B2/ja not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514868A (ja) * | 1995-10-13 | 1999-12-21 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ホスホパンテテイニルトランスフェラーゼおよびその使用 |
| JP2000503536A (ja) * | 1996-01-18 | 2000-03-28 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド | ヒト化グリーン蛍光タンパク質遺伝子および方法 |
| WO2002080958A1 (fr) * | 2001-02-28 | 2002-10-17 | Sichuan Biotechnology Research Center | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013514279A (ja) * | 2009-12-18 | 2013-04-25 | 四川▲輝▼▲陽▼生命工程股▲分▼有限公司 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
| JP2016128507A (ja) * | 2009-12-18 | 2016-07-14 | スーパーラブ ファー イースト リミテッド | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
| JP2016506413A (ja) * | 2013-01-07 | 2016-03-03 | スーパーラブ ファー イースト リミテッド | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2022516129A (ja) * | 2018-12-26 | 2022-02-24 | 上海元宋生物技術有限公司 | インターフェロンを発現する腫瘍溶解性ウイルス及びその応用 |
| JP7378840B2 (ja) | 2018-12-26 | 2023-11-14 | 上海元宋生物技術有限公司 | インターフェロンを発現する腫瘍溶解性ウイルス及びその応用 |
| US12319931B2 (en) | 2018-12-26 | 2025-06-03 | Shanghai Yuansong Biotechnology Co. Ltd. | Oncolytic virus expressing interferon and application therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2325202B1 (en) | 2014-10-22 |
| JP5709800B2 (ja) | 2015-04-30 |
| WO2005021777A2 (en) | 2005-03-10 |
| PL2325202T3 (pl) | 2015-03-31 |
| KR20060130009A (ko) | 2006-12-18 |
| AU2004279350B2 (en) | 2011-03-10 |
| EP1670817A2 (en) | 2006-06-21 |
| EP1663110A2 (en) | 2006-06-07 |
| CA2535982A1 (en) | 2005-04-21 |
| HK1091756A1 (en) | 2007-01-26 |
| AU2004269390A1 (en) | 2005-03-10 |
| HK1158231A1 (en) | 2012-09-14 |
| CA2535982C (en) | 2016-11-29 |
| PL1663110T3 (pl) | 2014-07-31 |
| JP2011083292A (ja) | 2011-04-28 |
| EP1663110B1 (en) | 2013-12-18 |
| WO2005034853A3 (en) | 2006-04-27 |
| WO2005034853A2 (en) | 2005-04-21 |
| EP1670817A4 (en) | 2008-07-16 |
| CA2535902A1 (en) | 2005-03-10 |
| WO2005021777A3 (en) | 2005-05-12 |
| EP2325202A1 (en) | 2011-05-25 |
| JP2012162567A (ja) | 2012-08-30 |
| JP5663768B2 (ja) | 2015-02-04 |
| AU2004279350A1 (en) | 2005-04-21 |
| JP2007516214A (ja) | 2007-06-21 |
| EP1663110A4 (en) | 2008-07-16 |
| KR20060133949A (ko) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011083292A (ja) | 空間構造によるタンパク質の機能の調節 | |
| WO2002080958A1 (fr) | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b | |
| JP2005508848A6 (ja) | コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用 | |
| AU2020382378A1 (en) | Nucleic acid lipid particle vaccine encapsulating HPV mRNA | |
| WO2005080419A1 (en) | Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof | |
| EP2341061B1 (en) | A novel process for preparing G-CSF (granulocyte colony stimulating factor) | |
| CN101747437B (zh) | 凋亡素-ec-sod羧基末端蛋白转导域融合蛋白 | |
| CN103193887A (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
| JP7707071B2 (ja) | コラーゲン７組成物を産生するための系および方法 | |
| Zhao et al. | Evaluating exosome protein content changes induced by virus activity using SILAC labeling and LC-MS/MS | |
| US20110070195A1 (en) | Uses of spatial configuration to modulate protein function | |
| CN114539426A (zh) | 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法 | |
| EP1511840A1 (en) | Process for preparing an adenovirus-containing preparation | |
| CN114681591A (zh) | HrpZpss蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 | |
| EP4144748A1 (en) | Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant | |
| US20240269160A1 (en) | Use Of Citicoline In Regulating Respiratory Chain Function Related Protein Level And Preparing Drug For Preventing And Treating Respiratory Chain Dysfunction | |
| RU2809358C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pET32a-IFG144, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ИНТЕРФЕРОНА ГАММА, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pET32a-IFG144 - ПРОДУЦЕНТ БЕЛКА ИНТЕРФЕРОН ГАММА, СПОСОБ ПОЛУЧЕНИЯ ИНТЕРФЕРОНА ГАММА И ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| RU2812047C1 (ru) | Вариант интерферона-бета человека с двойной мутацией и способ улучшения стабильности варианта интерферона-бета человека | |
| PT2325202E (pt) | Utilizações de interferões com estrutura espacial alterada | |
| CN115850512B (zh) | 一种用于靶向治疗肿瘤的重组融合蛋白及其制备方法 | |
| RU2180003C2 (ru) | Рекомбинантная плазмидная днк, обеспечивающая синтез фибробластного интерферона человека клетками дрожжей, способ ее конструирования и штамм дрожжей saccharomyces cerevisiae-продуцент фибробластного интерферона человека | |
| CN103864916B (zh) | 人胸腺肽β4三倍体蛋白、编码基因及其分离纯化方法 | |
| TWI328011B (en) | Recombinant super-compound interferon | |
| CN116041429A (zh) | 一种抑制黄嘌呤氧化酶活性的棘胸蛙多肽及其制备方法和应用 | |
| CN103013900B (zh) | msCT-AcAP5融合蛋白转基因工程菌株 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070823 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070914 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20070914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100510 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100806 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100902 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100927 |